EGFR and cancer: Consequently, ALK fusion proteins may circumvent anti-EGFR inhibition to activate downstream components of EGFR, thereby promoting cancer cell proliferation and survival, which could explain the possible mechanism of inner resistance to Cetuximab observed in our patients.